ORIGINAL PAPER

European Archives of Psychiatry and Clinical Neuroscience

, Volume 257, Issue 7, pp 383-388

The efficacy of the combination of sertraline with buspirone for smoking cessation

A randomized clinical trial in nondepressed smokers
  • Jorge Luiz CarrãoAffiliated withDepartment of Internal Medicine, Faculdade de Medicina, Universidade de Passo Fundo
  • , Leila Beltrami MoreiraAffiliated withDepartment of Pharmacology, Post-Graduate Program in Medical Sciences, Universidade Federal do Rio Grande do Sul Email author 
  • , Flávio Danni FuchsAffiliated withDivision of Cardiology, Serviço de Cardiologia, Sala 2061, Hospital de Clínicas de Porto Alegre, Post-Graduate Program in Medical Sciences, Universidade Federal do Rio Grande do Sul

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access

Abstract

In a double-blind placebo-controlled trial, we evaluated the efficacy of the combination of sertraline and buspirone plus cognitive-behavioral treatment to promote tobacco abstinence in individuals referred to a chemical dependency clinic. Ninety eight individuals 18–65 years of age were randomized to placebo or sertraline 25 mg/day for 2 days, followed by 50 mg from day 3 to 90, and buspirone 5 mg three times a day for 7 days, and 10 mg from day 8 to 90. The rate of continuous abstinence at the 26th week of follow-up, informed by the patient, was 43.5% in the active treatment group and 17.3% in the control group (= 0.01). The odds ratio for continuous abstinence for the intervention group was 4.74 (95% CI 1.50–14.55) (adjusted for smoker households and number of cognitive sessions). Nicotine withdrawal symptoms were common in both groups (98.7% vs. 95.5% = 0.37). The combination of sertraline and buspirone with cognitive-behavioral therapy was more effective than placebo and cognitive-behavioral therapy to promote smoking cessation.

Keywords

smoking cessation sertraline buspirone antidepressant anxiolytic